Tudor Investment Corp ET AL Purchases New Position in IDEAYA Biosciences, Inc. $IDYA

Key Points

• Tudor Investment Corp initiated a new position of 37,595 shares (~$1.02M) in Q3, joining large increases from Baker Bros., Balyasny, Dimensional and others, leaving 98.29% of IDYA held by hedge funds and institutional investors.
• Topline registrational results for darovasertib + crizotinib in a biomarker‑defined metastatic uveal melanoma population sparked a sharp stock rally and broader analyst/press attention; consensus rating is "Moderate Buy" with an average price target of $49.
• Director Jeffrey Stein purchased 50,000 shares at $32.96 (insiders own 2.5%), while the stock trades near $32.82 with a market cap of $2.88B, reflecting clinical‑stage upside but ongoing biotech risk.

Tudor Investment Corp ET AL purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 37,595 shares of the company's stock, valued at approximately $1,023,000.

Several other institutional investors also recently bought and sold shares of IDYA. Baker BROS. Advisors LP raised its position in IDEAYA Biosciences by 54.6% during the third quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company's stock valued at $89,125,000 after acquiring an additional 1,156,716 shares in the last quarter. Millennium Management LLC raised its position in IDEAYA Biosciences by 345.2% during the first quarter. Millennium Management LLC now owns 547,637 shares of the company's stock valued at $8,970,000 after acquiring an additional 424,625 shares in the last quarter. Balyasny Asset Management L.P. raised its position in IDEAYA Biosciences by 1,619.5% during the third quarter. Balyasny Asset Management L.P. now owns 380,311 shares of the company's stock valued at $10,348,000 after acquiring an additional 358,194 shares in the last quarter. Dimensional Fund Advisors LP raised its position in IDEAYA Biosciences by 191.2% during the third quarter. Dimensional Fund Advisors LP now owns 497,048 shares of the company's stock valued at $13,525,000 after acquiring an additional 326,376 shares in the last quarter. Finally, Fiera Capital Corp raised its position in IDEAYA Biosciences by 20.0% during the third quarter. Fiera Capital Corp now owns 1,837,967 shares of the company's stock valued at $50,011,000 after acquiring an additional 305,698 shares in the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

More IDEAYA Biosciences News

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: Topline registrational results show a large PFS improvement and strong statistical signal, supporting a potential approval pathway for darovasertib + crizotinib in a biomarker‑defined mUM population. PR Newswire: OptimUM-02 Topline Results
• Positive Sentiment: Market reaction and coverage: major outlets report the data and the stock moved sharply higher on heavy trading — this increases visibility and could accelerate analyst/partner interest. Barron's: Stock Jumps on Trial Results
• Neutral Sentiment: Registrational designation with Servier means a clear regulatory pathway if full data and safety support the topline — watch timing for full dataset publication, regulatory meetings and submission plans. Coverage summarizes the result but full package and label scope remain forthcoming. Yahoo Finance: Positive Topline Results
• Neutral Sentiment: Analyst stance: consensus remains a "Moderate Buy" from recent analyst coverage — analysts will likely revisit models after full data and regulatory details. American Banking News: Analyst Consensus
• Negative Sentiment: Caveats and uncertainty: commentators note approval is not automatic — regulators will review safety, confirmatory endpoints (overall survival), subgroup/OS data and manufacturing/commercial plans; patient population is small (mUM), limiting peak revenues even if approved. Seeking Alpha: Approval Not a Formality

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. UBS Group initiated coverage on IDEAYA Biosciences in a research report on Wednesday, January 7th. They set a "buy" rating and a $50.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Wedbush restated an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, March 31st. Royal Bank Of Canada restated an "outperform" rating and issued a $49.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Finally, Citigroup boosted their price objective on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $49.00.

IDEAYA Biosciences Price Performance

Shares of NASDAQ:IDYA opened at $32.82 on Tuesday. The business's 50 day moving average price is $32.41 and its 200-day moving average price is $32.58. The firm has a market capitalization of $2.88 billion, a PE ratio of -25.05 and a beta of 0.02. IDEAYA Biosciences, Inc. has a 1 year low of $15.84 and a 1 year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.09. The firm had revenue of $10.88 million during the quarter, compared to analyst estimates of $5.95 million. The business's revenue was up 55.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.49) earnings per share. As a group, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Jeffrey Stein acquired 50,000 shares of the stock in a transaction on Monday, March 2nd. The shares were bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the purchase, the director owned 54,281 shares of the company's stock, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.50% of the company's stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.